Genmab — Juli 2016
-
-
"..patients with early stage disease, who had received only 1 prior line of therapy, and/or had not received prior bortezomib, had a PFS advantage. Dr. Palumbo says these results support the use of daratumumab earlier in the disease course."
-
Kongetallet i massivt comeback.
http://borsen.dk/nyheder/oekonomi/artikel/1/327646/kongetallet_goer_massivt_comeback_287000_nye_job_i_usa.html -
Bristol Myers' small deal underscores how hot immuno-oncology is - MedCity News
BMS' purchase of Cormorant shows that no deal is too small when it comes to immuno-oncology.
MedCity News (medcitynews.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind